BRIEF-Sangamo BioSciences announces FDA clearance

Sangamo BioSciences Inc: * To initiate SB-913-1602 scientific research study for MPS II in
second half of 2016

* Announces FDA clearance of investigational new drug
application for ZFN-mediated genome modifying treatment of MPS II

Source text for Eikon:
Further business coverage:

( Bengaluru Newsroom: +1 -646 -223 -8780).

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *